AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11519931 — intervention group
Group type: EXPERIMENTAL
Intervention: In-the-moment self-regulatory strength
Number of subjects: 0
Study 11519931 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control (Study 3)
Number of subjects: 0
Study 9575997 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable hook cautery instruments
Number of subjects: 0
Study 9575997 — intervention group
Group type: COMPARATOR
Intervention: Limited-reuse hook cautery instruments
Number of subjects: 0
Study 9575997 — intervention group
Group type: COMPARATOR
Intervention: Limited-reuse curved scissors
Number of subjects: 0
Study 8157768 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg daily)
Number of subjects: 47
Study 8157768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3046405 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracts composed of any combination of alder, birch and hazel pollen (Group 1 (ABC))
Number of subjects: 54
Study 3046405 — intervention group
Group type: COMPARATOR
Intervention: Birch pollen extracts (Group 2 (B))
Number of subjects: 54
Study 31809359 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized recommendation
Number of subjects: 236
Study 31809359 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV testing information
Number of subjects: 236
Study 30222831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use in Case 1 (no bleeding)
Number of subjects: 4
Study 30222831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use in Case 2 (limb-wound bleeding)
Number of subjects: 4
Study 30222831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use in Case 3 (child with limb-wound bleeding)
Number of subjects: 4
Study 30222831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use in Case 4 (limb-wound bleeding under gunfire)
Number of subjects: 4
Study 30222831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use in Case 5 (two tourniquets side by side under gunfire)
Number of subjects: 4
Study 30222831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical performance across all cases
Number of subjects: 4
Study 30222831 — intervention group
Group type: EXPERIMENTAL
Intervention: Block 1 (first block of tests)
Number of subjects: 4
Study 30222831 — intervention group
Group type: EXPERIMENTAL
Intervention: Block 2 (second block of tests)
Number of subjects: 4
Study 30222831 — intervention group
Group type: EXPERIMENTAL
Intervention: Block 3 (third block of tests)
Number of subjects: 4
Study 27760790 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0
Study 26591200 — intervention group
Group type: EXPERIMENTAL
Intervention: b2-adrenomimetic (fenoterol)
Number of subjects: 0
Study 26591200 — intervention group
Group type: EXPERIMENTAL
Intervention: anticholinergic (ipratropium bromide)
Number of subjects: 0
Study 26591200 — intervention group
Group type: EXPERIMENTAL
Intervention: combined preparation (fenoterol/ipratropium bromide)
Number of subjects: 0
Study 23747795 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial hepatic (TAH) delivery of indocyanine green (ICG)
Number of subjects: 9
Study 23747795 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) delivery of indocyanine green (ICG)
Number of subjects: 9
Study 23747795 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TAH vs IV delivery of ICG
Number of subjects: 9
Study 21627558 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week and calcium with vitamin D
Number of subjects: 80
Study 21627558 — intervention group
Group type: COMPARATOR
Intervention: Calcium with vitamin D
Number of subjects: 80
Study 21627558 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 80
Study 18978619 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning rowing performance (M-type subjects)
Number of subjects: 16
Study 18978619 — intervention group
Group type: COMPARATOR
Intervention: Evening rowing performance (E-type and N-type subjects)
Number of subjects: 16
Study 18978619 — intervention group
Group type: COMPARATOR
Intervention: Standing broad jump performance
Number of subjects: 16
Study 16552372 — intervention group
Group type: EXPERIMENTAL
Intervention: Single mesh technique
Number of subjects: 65
Study 16552372 — intervention group
Group type: COMPARATOR
Intervention: Double mesh technique
Number of subjects: 65
Study 12679710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status improvement and treatment of parasitic infections
Number of subjects: 957
Study 12679710 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MUAC, education level, serum retinol and selenium concentrations, clinical stage of HIV disease, malaria infection
Number of subjects: 957
Study 12679710 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline CD4 T-cell counts
Number of subjects: 957
Study 12679710 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain measurement
Number of subjects: 957
Study 12679710 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in mid-upper arm circumference (MUAC)
Number of subjects: 957
Study 10999648 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol/niacin
Number of subjects: 2
Study 10999648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 2
Study 10999648 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2
Study 9457388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2, day 0) plus continuous intravenous infusion rIL-2 (18 MIU/m2/day, days 3-6 and days 17-21) and subcutaneous rIFN-alpha (9 MIU three times per week)
Number of subjects: 129
Study 9457388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus rIL-2 and rIFN-alpha
Number of subjects: 129
Study 9457388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus rIL-2 and rIFN-alpha with tamoxifen (160 mg/day)
Number of subjects: 129
Study 8440759 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (20, 50, 80 mg)
Number of subjects: 22
Study 8440759 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20, 50, 80 mg)
Number of subjects: 22
Study 8440759 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (20, 50, 80 mg)
Number of subjects: 22
Study 8440759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 4063010 — intervention group
Group type: EXPERIMENTAL
Intervention: Community nursing homes (CNHs)
Number of subjects: 403
Study 4063010 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans Administration nursing care units
Number of subjects: 403
Study 4063010 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued care on the same ward
Number of subjects: 403
Study 4063010 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer to another psychiatric ward
Number of subjects: 403
Study 4063010 — intervention group
Group type: COMPARATOR
Intervention: Drug use
Number of subjects: 403
Study 4063010 — intervention group
Group type: COMPARATOR
Intervention: Cost
Number of subjects: 403
Study 31296273 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma applied to the tonsillar bed post-operatively
Number of subjects: 0
Study 31296273 — intervention group
Group type: COMPARATOR
Intervention: Control side (no intervention)
Number of subjects: 0
Study 29421003 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning the instrumented right arm far from the body
Number of subjects: 14
Study 29421003 — intervention group
Group type: COMPARATOR
Intervention: Positioning the instrumented right arm close to the right leg
Number of subjects: 14
Study 29421003 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a smaller full glass shield
Number of subjects: 14
Study 29421003 — intervention group
Group type: COMPARATOR
Intervention: Use of a larger composite shield
Number of subjects: 14
Study 27866182 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (9 drugs including Pulsatilla nigricans, Sepia succus, Lycopodium clavatum, sulphur, Lachesis trigonocephalus, Nux vomica, Calcarea carbonica, phosphorus, Conium maculatum) administered as 6 drops orally 2 times per day for 4 consecutive days each week, with a 3-day interval between doses.
Number of subjects: 134
Study 27866182 — intervention group
Group type: COMPARATOR
Intervention: Control group received placebo drug and diet orientation.
Number of subjects: 134
Study 27866182 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 134
Study 27866182 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study 1444292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime, 2 g intravenously at 6‐h intervals during surgery and then at 8‐h intervals thereafter for 48 h
Number of subjects: 18
Study 1444292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin, 2 g intravenously at the same dose and schedule as cefotaxime
Number of subjects: 18
Study 1444292 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics plus a 3‐week regimen of oral nonabsorbable antibiotics (gentamicin, polymyxin E, and nystatin)
Number of subjects: 18
Study 1444292 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics alone
Number of subjects: 18
Study 22902138 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral grade III mobilization of the talocrural joint
Number of subjects: 32
Study 22902138 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study 20412151 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 100
Study 20412151 — intervention group
Group type: COMPARATOR
Intervention: McCoy laryngoscope
Number of subjects: 100
Study 18708988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular lumbar facet joint injections with lidocaine and triamcinolone
Number of subjects: 46
Study 18708988 — intervention group
Group type: COMPARATOR
Intervention: Medial branch nerve blocks with lidocaine and triamcinolone
Number of subjects: 46
Study 15877992 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (6 months)
Number of subjects: 15
Study 15877992 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 15
Study 12209099 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/d for 6 weeks
Number of subjects: 30
Study 12209099 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 30
Study 10604096 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pancreatitis
Number of subjects: 72
Study 10604096 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pancreatitis
Number of subjects: 72
Study 10604096 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic carcinoma
Number of subjects: 72
Study 10604096 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 72
Study 8961368 — intervention group
Group type: COMPARATOR
Intervention: Whole Brain Irradiation (WBI)
Number of subjects: 30
Study 8961368 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Irradiation (FI)
Number of subjects: 30
Study 1763561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid (AA) therapy (225 meq total neutralizing capacity per day)
Number of subjects: 100
Study 1763561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid (AA) therapy
Number of subjects: 100
Study 1763561 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (MS) therapy (400 micrograms bid)
Number of subjects: 100
Study 1763561 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (MS) therapy
Number of subjects: 100
Study 6433840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose urokinase (UKl): 2000 IU/kg/hour associated with heparin
Number of subjects: 129
Study 6433840 — intervention group
Group type: COMPARATOR
Intervention: High dose urokinase (UKh): 4400 IU/kg/hour for 12 hours followed by heparin
Number of subjects: 129
Study 6433840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose urokinase (UKl)
Number of subjects: 129
Study 6433840 — intervention group
Group type: COMPARATOR
Intervention: High dose urokinase (UKh)
Number of subjects: 129
Study 6433840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 129
Study 31567622 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial diagnosis of glaucoma based on strict criteria from 2 visual field tests and optic disc findings if borderline
Number of subjects: 255
Study 31567622 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial diagnosis of glaucoma
Number of subjects: 255
Study 29630134 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole sequential therapy
Number of subjects: 110
Study 29630134 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 110
Study 27292585 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy every 2 weeks for 15 weeks
Number of subjects: 94
Study 27292585 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment every 2 weeks for 15 weeks
Number of subjects: 94
Study 24256699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/day)
Number of subjects: 68
Study 24256699 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg/day)
Number of subjects: 68
Study 24256699 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluvastatin (40 mg/day) and diltiazem (90 mg/day)
Number of subjects: 68
Study 22479786 — intervention group
Group type: EXPERIMENTAL
Intervention: HM-302 mouth rinse
Number of subjects: 62
Study 22479786 — intervention group
Group type: COMPARATOR
Intervention: Cetylpyridinium chloride (CPC) rinse
Number of subjects: 62
Study 22479786 — intervention group
Group type: COMPARATOR
Intervention: Essential oils (EO) rinse
Number of subjects: 62
Study 22479786 — intervention group
Group type: COMPARATOR
Intervention: Water-only preparation
Number of subjects: 62
Study 21427997 — intervention group
Group type: EXPERIMENTAL
Intervention: indigal plus (2 capsules twice a day for 3 months) and sparfloxacin (200 mg twice a day for 1 month)
Number of subjects: 30
Study 21427997 — intervention group
Group type: COMPARATOR
Intervention: sparfloxacin alone (200 mg twice a day for 1 month)
Number of subjects: 30
Study 18042106 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg every 4 weeks for 48 weeks (N=168)
Number of subjects: 339
Study 18042106 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 48 weeks (N=171)
Number of subjects: 339
Study 17885311 — intervention group
Group type: EXPERIMENTAL
Intervention: Object present (holding a glass)
Number of subjects: 66
Study 17885311 — intervention group
Group type: COMPARATOR
Intervention: Object absent (no object)
Number of subjects: 66
Study 15574070 — intervention group
Group type: EXPERIMENTAL
Intervention: KLIP program (knee ligament injury prevention program), low-intensity plyometric exercises, 9 weeks duration, twice a week
Number of subjects: 28
Study 15574070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 10881808 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal Matrix
Number of subjects: 93
Study 10881808 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam‐Thrombin (control group)
Number of subjects: 93
Study 9178671 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice daily
Number of subjects: 104
Study 9178671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 1489073 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium aspartate infusion (0.8 mEq/kg per h for 15 min, then reduced to 0.2 mEq/kg per h until aortic cannulation)
Number of subjects: 18
Study 1489073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium infusion)
Number of subjects: 18
Study 1489073 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium aspartate infusion
Number of subjects: 18
Study 1489073 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 4045758 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct informational feedback using videotape recordings
Number of subjects: 8
Study 30704873 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day)
Number of subjects: 257
Study 30704873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 28659614 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS) applied for 10 minutes to the more affected motor cortex.
Number of subjects: 0
Study 28659614 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 0
Study 28659614 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS) ON medication.
Number of subjects: 0
Study 26309023 — intervention group
Group type: COMPARATOR
Intervention: Rapid Diagnostic Tests (RDTs) with basic instruction (control)
Number of subjects: 4946
Study 26309023 — intervention group
Group type: EXPERIMENTAL
Intervention: RDTs with provider training (provider arm)
Number of subjects: 4946
Study 26309023 — intervention group
Group type: EXPERIMENTAL
Intervention: RDTs with provider training plus a school‐based community intervention (provider‐school arm)
Number of subjects: 4946
Study 24339699 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg intravenously at week 0, 2, 6, 14, and 22 with methotrexate maintenance
Number of subjects: 143
Study 24339699 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment during the extension study
Number of subjects: 143
Study 24339699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 24339699 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab and methotrexate
Number of subjects: 143
Study 21385988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant 20 mg
Number of subjects: 619
Study 21385988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant 70 mg
Number of subjects: 619
Study 21385988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant 200 mg
Number of subjects: 619
Study 21385988 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg (active control)
Number of subjects: 619
Study 21385988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 17653859 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 17653859 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 16813478 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) applied to the gastrocnemius‐soleus muscle complex for 15 trials
Number of subjects: 13
Study 16813478 — intervention group
Group type: COMPARATOR
Intervention: No functional electrical stimulation (no FES) for 15 trials
Number of subjects: 13
Study 16813478 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 13
Study 16813478 — intervention group
Group type: COMPARATOR
Intervention: No functional electrical stimulation (no FES)
Number of subjects: 13
Study 12677608 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified soft drink
Number of subjects: 15
Study 12677608 — intervention group
Group type: COMPARATOR
Intervention: Original soft drink
Number of subjects: 15
Study 10729389 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat diet (21% energy from saturated fat, 3% energy from polyunsaturated fat)
Number of subjects: 46
Study 10729389 — intervention group
Group type: COMPARATOR
Intervention: High polyunsaturated fat diet (11% energy from saturated fat, 10% energy from polyunsaturated fat)
Number of subjects: 46
Study 10729389 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo AIV Q/H individuals (n=6)
Number of subjects: 46
Study 10729389 — intervention group
Group type: COMPARATOR
Intervention: Apo AIV Q/Q individuals
Number of subjects: 46
Study 9014006 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated combined vaccine (ICV) against Q fever
Number of subjects: 30
Study 9014006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1547611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-annual topical APF gel applications
Number of subjects: 488
Study 1547611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488
Study 2860494 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 120
Study 2860494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-potassium di-citrato bismuthate (TDB) tablet four times a day
Number of subjects: 120
Study 30672127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Number of subjects: 0
Study 30672127 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet
Number of subjects: 0
Study 30672127 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Reported Energy Intake (∆EIRecall)
Number of subjects: 0
Study 30672127 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective Energy Intake (∆EIModel)
Number of subjects: 0
Study 28801122 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum deoxycholic acid concentration > 58ng/mL
Number of subjects: 112
Study 28801122 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline deoxycholic acid concentrations
Number of subjects: 112
Study 27570866 — intervention group
Group type: COMPARATOR
Intervention: NICE guidelines
Number of subjects: 1202
Study 27570866 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR
Number of subjects: 1202
Study 27570866 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS
Number of subjects: 1202
Study 24907195 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery group (skin grafting)
Number of subjects: 200
Study 24907195 — intervention group
Group type: COMPARATOR
Intervention: Control group (conservative treatment)
Number of subjects: 200
Study 22614394 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch with a soft elastomer brush
Number of subjects: 0
Study 22614394 — intervention group
Group type: COMPARATOR
Intervention: Touch with a flat disc
Number of subjects: 0
Study 20705902 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg) with paroxetine (10 mg orally twice daily)
Number of subjects: 12
Study 20705902 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (12.5 mg) without paroxetine
Number of subjects: 12